The Economics of Reproducibility in Preclinical Research
Abstract
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US28,000,000,000 (US8B)/year spent on preclinical research that is not reproducible—in the United States alone. We...
Paper Details
Title
The Economics of Reproducibility in Preclinical Research
Published Date
Jun 9, 2015
Journal
Volume
13
Issue
6
Pages
1 - 9
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History